New updates have been reported about Pinetree Therapeutics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PineTree Therapeutics will receive a $25 million payment after AstraZeneca exercised its option to obtain exclusive global rights to PTX-299, a first-in-class bispecific antibody degrader developed on PineTree’s AbReptor platform to target EGFR in cancer. Under the existing collaboration, AstraZeneca will now take over worldwide development and commercialization of PTX-299, positioning PineTree as a platform innovator while shifting late-stage R&D and commercial risk to its larger partner.
The deal structure provides PineTree with significant long-term upside: the company is eligible for additional development, regulatory, and commercial milestones plus tiered royalties on global net sales, with total potential deal value exceeding $500 million if PTX-299 is successfully brought to market. Strategically, the transaction validates PineTree’s antibody-based protein degradation technology, which is designed to remove disease-driving EGFR proteins rather than only inhibit them, and supports the broader AbReptor pipeline, including trispecific degraders and ADC-integrated platforms targeting oncology and immune-driven diseases.